 Wave Life Sciences Ltd NASDAQ: WVE has amended its ongoing collaboration with Takeda Pharmaceutical Company Limited NYSE: TAK to discontinue discovery research of preclinical programs for central nervous system CNS indications over a four-year research term. Under terms of the amendment, Takeda will pay Wave 22.5 million for collaboration-related research and preclinical expenses. 